{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae FT4",
        "LIAISON\u00ae Control Thyroid 1",
        "LIAISON\u00ae Control Thyroid 2",
        "LIAISON\u00ae Control Thyroid 3"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K121951",
    "Predicate Device Reference 510(k) Number(s)": [
        "K961489",
        "K090541"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEC",
        "JJX"
    ],
    "Summary Letter Date": "March 25, 2013",
    "Summary Letter Received Date": "March 28, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1695",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Free thyroxine test system",
        "Quality control material"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Free thyroxine (FT4)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Solid Phase Antigen Linked Technique (SPALT)"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON FT4 chemiluminescent immunoassay and control materials for quantitative determination of free thyroxine in serum using the LIAISON Analyzer",
    "Indications for Use Summary": "Intended for quantitative determination of free thyroxine (FT4) in human serum using the LIAISON Analyzer as an aid in the clinical assessment of thyroid status; controls are for monitoring accuracy and precision of the assay.",
    "fda_folder": "Clinical Chemistry"
}